CA3157464A1 - Aav vector variants for ocular gene delivery - Google Patents

Aav vector variants for ocular gene delivery

Info

Publication number
CA3157464A1
CA3157464A1 CA3157464A CA3157464A CA3157464A1 CA 3157464 A1 CA3157464 A1 CA 3157464A1 CA 3157464 A CA3157464 A CA 3157464A CA 3157464 A CA3157464 A CA 3157464A CA 3157464 A1 CA3157464 A1 CA 3157464A1
Authority
CA
Canada
Prior art keywords
seq
capsid
aav
acid sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3157464A
Other languages
English (en)
French (fr)
Inventor
Sonja Kleinlogel
Anand DAVID
Hildegard Buning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bern
Hannover Medical School
Original Assignee
University of Bern
Hannover Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bern, Hannover Medical School filed Critical University of Bern
Publication of CA3157464A1 publication Critical patent/CA3157464A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3157464A 2019-10-31 2020-11-02 Aav vector variants for ocular gene delivery Pending CA3157464A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206603 2019-10-31
EP19206603.3 2019-10-31
PCT/EP2020/080704 WO2021084133A1 (en) 2019-10-31 2020-11-02 Aav vector variants for ocular gene delivery

Publications (1)

Publication Number Publication Date
CA3157464A1 true CA3157464A1 (en) 2021-05-06

Family

ID=68426130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3157464A Pending CA3157464A1 (en) 2019-10-31 2020-11-02 Aav vector variants for ocular gene delivery

Country Status (9)

Country Link
US (1) US12509705B2 (cg-RX-API-DMAC7.html)
EP (1) EP4051694B1 (cg-RX-API-DMAC7.html)
JP (1) JP7791546B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220093163A (cg-RX-API-DMAC7.html)
CN (1) CN114729009A (cg-RX-API-DMAC7.html)
AU (1) AU2020373326A1 (cg-RX-API-DMAC7.html)
CA (1) CA3157464A1 (cg-RX-API-DMAC7.html)
IL (1) IL291240A (cg-RX-API-DMAC7.html)
WO (1) WO2021084133A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4349852A4 (en) * 2021-05-28 2025-09-03 Shanghai Regenelead Therapies Co Ltd RECOMBINANT ADENO-ASSOCIATED VIRUS HAVING A VARIANT CAPSID, AND ITS APPLICATION
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
KR20240152351A (ko) * 2022-02-17 2024-10-21 스카이라인 테라퓨틱스 리미티드 변형된 aav 캡시드 폴리펩티드를 갖는 재조합 아데노-연관 바이러스
JP2026509271A (ja) 2023-03-10 2026-03-17 ダイノ セラピューティクス,インコーポレーテッド カプシドポリペプチドおよびその使用方法
CN121219325A (zh) * 2023-05-23 2025-12-26 北京因诺惟康医药科技有限公司 一种腺相关病毒衣壳蛋白、包含其的腺相关病毒、载体及应用
KR20260082361A (ko) 2023-08-31 2026-06-04 디노 테라퓨틱스, 인코포레이티드 캡시드 폴리펩타이드 및 이의 사용 방법
WO2025051292A1 (zh) * 2024-01-16 2025-03-13 广州译码基因科技有限公司 提高aav病毒对眼组织感染能力的衣壳蛋白突变体及其应用
CN118440161B (zh) * 2024-01-16 2025-02-25 沈阳兴齐眼药股份有限公司 提高aav病毒视网膜穿透能力的衣壳蛋白突变体及其应用
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
US20260042803A1 (en) * 2024-08-09 2026-02-12 Revvity Gene Delivery Gmbh Variant aav capsid polypeptides targeting the eye
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026122963A1 (en) 2024-12-06 2026-06-11 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2026123017A1 (en) * 2024-12-06 2026-06-11 General Medicines Inc. Compositions and methods for improved adeno-associated viral gene therapy
WO2026160681A1 (ko) * 2025-01-24 2026-07-30 연세대학교 산학협력단 망막 세포 표적화 아데노-관련 바이러스 변이체 kap 및 그의 용도
WO2026160680A1 (ko) * 2025-01-24 2026-07-30 연세대학교 산학협력단 망막 세포 표적화 아데노-관련 바이러스 변이체 adn 및 그의 용도

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
WO1997005252A2 (en) 1995-07-26 1997-02-13 Nps Pharmaceuticals, Inc. Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US20040248202A1 (en) 1998-09-03 2004-12-09 Wisconsin Alumni Research Foundation Bacteriorhodopsin/G protein-coupled receptor chimeras
US9284363B2 (en) 2006-07-26 2016-03-15 Case Western Reserve University System and method for controlling G-protein coupled receptor pathways
EP2294208B1 (en) 2008-05-29 2013-05-08 The Board of Trustees of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
GB2498325B (en) 2010-10-15 2018-05-02 Eos Neuroscience Inc Engineered human GRM6 enhancer sequence for use in eye therapies
DK3693025T3 (da) * 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
CA2840458C (en) 2011-06-24 2020-09-22 Haag-Streit Medtech Ag Light-sensitive chimeric gpcr protein
WO2013003557A1 (en) 2011-06-28 2013-01-03 University Of Rochester Photoactivatable receptors and their uses
US20140087463A1 (en) 2012-09-25 2014-03-27 The Washington University Optical control of cell signaling
RU2664471C2 (ru) 2013-07-26 2018-08-17 Юниверсити Оф Айова Рисерч Фаундейшн Способы и композиции для лечения болезней мозга
KR102234695B1 (ko) 2014-02-06 2021-04-02 젠자임 코포레이션 황반 변성을 치료하고 예방하기 위한 조성물 및 방법
WO2015126972A1 (en) 2014-02-21 2015-08-27 University Of Florida Research Foundation, Inc. Methods and compositions for gene delivery to on bipolar cells
GB201403260D0 (en) 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
US10307492B2 (en) 2014-03-11 2019-06-04 Wayne State University Modified MGLUR6 promoter and methods of use
CA2977355A1 (en) * 2015-02-20 2016-08-25 University Of Iowa Research Foundation Methods and compositions for treating genetic eye diseases
FI3265178T3 (fi) 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
WO2016149664A1 (en) 2015-03-18 2016-09-22 University Of Florida Research Foundation, Inc. Methods and compositions for restoration of cone function in bcm
CN105154470A (zh) 2015-07-22 2015-12-16 华东师范大学 一种高效筛查g蛋白-偶联受体表达的融合基因构建方法
WO2017197355A2 (en) 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
CN109640949B (zh) 2016-07-29 2022-11-25 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体和其使用方法
EP3508212B1 (en) 2016-09-02 2025-10-22 Keio University Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
US10376265B2 (en) 2017-01-30 2019-08-13 Ethicon Llc Non-magnetic fragmentable tissue compression devices
KR20250023600A (ko) * 2017-06-30 2025-02-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
AU2018350700B2 (en) * 2017-10-16 2025-04-24 VeonGen Therapeutics GmbH AAV vectors
JP7029160B2 (ja) 2017-11-24 2022-03-03 公立大学法人大阪 新規な光受容タンパク質
US11766489B2 (en) 2017-11-27 2023-09-26 4D Molecular Therapeutics, Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
CA3127535A1 (en) 2019-01-18 2020-07-23 Restore Vision Inc. Preventing, and suppressing progression of, retinal disease, improving visual cognitive behavioral function, and strengthening visual function
AU2020385619B2 (en) 2019-11-18 2023-06-01 Universität Bern On-bipolar cell-specific promoters for ocular gene delivery
KR20220111294A (ko) 2019-11-29 2022-08-09 유니버시태트 베른 키메라 옵신 gpcr 단백질

Also Published As

Publication number Publication date
AU2020373326A1 (en) 2022-06-02
EP4051694B1 (en) 2025-07-02
EP4051694A1 (en) 2022-09-07
JP2023504773A (ja) 2023-02-07
US20240287542A1 (en) 2024-08-29
EP4051694C0 (en) 2025-07-02
WO2021084133A1 (en) 2021-05-06
IL291240A (en) 2022-05-01
CN114729009A (zh) 2022-07-08
KR20220093163A (ko) 2022-07-05
JP7791546B2 (ja) 2025-12-24
US12509705B2 (en) 2025-12-30

Similar Documents

Publication Publication Date Title
EP4051694B1 (en) Aav vector variants for ocular gene delivery
RU2742724C1 (ru) Вирионы аденоассоциированного вируса с вариантным капсидом и способы их использования
AU2016219789B2 (en) Methods and compositions for treating genetic eye diseases
JP2022174192A (ja) 多重ベクターシステム及びその使用
CA3244355A1 (en) RECOMBINANT ADENOVIRUS-ASSOCIATED VIRUS (AAV) COMPRISING MODIFIED AAV CAPSID POLYPEPTIDES
KR20240023126A (ko) 망막 장애
KR20240010489A (ko) 시력 기능 향상을 위한 조성물 및 방법
CN116368228A (zh) 用于治疗眼部疾病的组合物和方法
US20240307559A1 (en) Kcnv2 gene therapy
KR20240005950A (ko) 벡터 시스템
CN112522276B (zh) 一种emc1核苷酸序列及其应用
US20260041791A1 (en) Compositions and methods for treatment of achromotopsia
CN117337331A (zh) 用于增强视觉功能的组合物和方法
WO2024160770A1 (en) An aav9 capsid variant for targeted gene transfer
IL321968A (en) Recombinant adeno-associated virus vector
HK40035863A (en) Adeno-associated virus virions with variant capsid and methods of use thereof
HK40035863B (en) Adeno-associated virus virions with variant capsid and methods of use thereof
CN119894920A (zh) 用于靶向神经系统的新型aav衣壳及其用途
CN112063625A (zh) 编码arl2bp的核酸及其应用
HK1247855B (en) Adeno-associated virus virions with variant capsid and methods of use thereof
HK1194982B (en) Adeno-associated virus virions with variant capsid and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220920

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250825

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260504